ProPhase Labs

PRPHPre-clinical

ProPhase Labs is a publicly-traded, diversified healthcare company executing a synergistic strategy across three core areas: genomics, biopharma, and consumer health. The company has generated significant revenue through its CLIA-certified lab operations and consumer products, while investing in high-potential assets like the BE-Smart esophageal cancer detection test and Equivir antiviral compounds. Led by Chairman & CEO Ted Karkus, who has a track record of building and selling companies for substantial returns, ProPhase aims to become a multibillion-dollar company through focused execution and smart diversification of its cutting-edge assets.

Market Cap

$238.3M

Focus

Generic Drugs

PRPH · Stock Price

USD 50.30+30.50 (+154.04%)

Historical price data

AI Company Overview

Technology Platform

Whole genome sequencing platform for consumer and healthcare applications; diagnostic development platform for cancer detection; drug development capabilities for antivirals and oncology therapeutics.

Opportunities

Large market opportunities in genomics, cancer diagnostics, and antiviral therapeutics.

Diversified business model provides revenue stability while pursuing high-potential biopharma assets.

Potential monetization of BE-Smart test could provide capital for further growth.

Risk Factors

Early-stage pipeline faces typical drug development failure risks.

Highly competitive markets across all business segments.

Diversified model requires complex execution across different business cycles and expertise areas.

Competitive Landscape

Faces competition from established players in genomics (23andMe, Illumina), cancer diagnostics (Exact Sciences, Guardant Health), and antivirals (Gilead, Merck). Differentiates through diversified revenue streams, competitive whole genome sequencing pricing, and focus on esophageal cancer detection where screening options are limited.